The San Diego Business Journal (SDBJ) recognizes Dr. Crooke as an icon for his remarkable impact on the San Diego region.
SAN DIEGO, Calif., Nov. 22, 2023, (BUSINESS WIRE) n-Lorem, a nonprofit foundation, announced Stanley T. Crooke, M.D., Ph.D., the founder and CEO of n-Lorem, has been honored as an Icon by the San Diego Business Journal with inclusion in the 2023 SD 500, a recognition that highlights the 500 most influential individuals in San Diego.
Dr. Crooke is considered one of the top icons in San Diego for materializing and advancing a new RNA-targeted drug discovery platform and for his work developing and establishing the n-Lorem foundation to charitably discover, develop, and provide personalized experimental antisense oligonucleotide (ASO) medicines for patients with some the world’s rarest genetic mutations.
San Diego 500 members actively contribute to the economic vitality of the region. Numerous individuals dedicate themselves to constructing or enhancing the broader community. However, a few members stand out for their exceptional influence and significant contributions, earning them the esteemed recognition as icons by the San Diego Business Journal.
Dr. Crooke founded n-Lorem Foundation in 2020 as the first, industrialized non-profit foundation to meet the challenges of some of the rarest of rare patients – nano-rare patients, which have illnesses so rare that fewer than 30 people worldwide are afflicted with them. These patients often have no treatment options because their illnesses are too rare for for-profit companies to invest in the research and development of therapies. Once n-Lorem discovers and develops a personalized treatment for each individual nano-rare patient, the ASO therapy is provided free for life.
As a hands-on scientific leader his entire career, Dr. Crooke is credited with inventing, advancing and validating a new drug discovery platform, RNA-targeted drug discovery, and using this platform to discover and develop life-changing therapies. Over the course of his career, Dr. Crooke has led the discovery and development of hundreds of drugs, including more than 23 commercialized drugs, and published more than 500 scientific publications.
Dr. Crooke has received a number of awards that celebrate his impactful and lasting impression on the world. Most recently, the Indiana University School of Medicine Steven C. Beering Award, and the Prix Galien Roy Vagelos Pro Bono Humanum Award in recognition for his nearly 50 years of dedication to a novel, clinically endorsed concept of using synthetic oligonucleotides to control the expression of genes and proteins that impact disease.
Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.
- Watch: Hope is Possible: n-Lorem Foundation
- Watch: Stan Receives the 2022 Roy Vagelos Pro Bono Humanum Award
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has received over 225 applications for treatment with approximately 100 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.
To learn more about n-Lorem’s mission, visit www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.
Amy Williford, Ph.D.
Sr. Director of Communications